Μετάβαση στο περιεχόμενο

Current Treatment Tracker

Child date of birth: 08/04/2021. As of 2026-04-09, the child is 5 years old (turned 5 on 2026-04-08).

This page is the running tracker for clinician-directed prescriptions and practical follow-up in this specific child. It is separate from the broader background pages on Treatments and Solutions and Available Products & Treatment Plan.

Current active entries

Date added Item Status Working note
2026-04-09 Xozal oral solution (levocetirizine 0.5 mg/ml) Prescribed / higher-than-label pediatric dose The doctor-prescribed dose has been confirmed as 10 ml every night. The child also has eczema-related itch plus urticaria/hives, which makes this look more like a clinician-directed antihistamine plan for a mixed eczema-plus-urticaria picture than routine eczema treatment alone.

2026-04-09: Xozal (levocetirizine) entry

Observation

  • A doctor recommendation was recorded on 2026-04-09 as: "Xozal 10cc/ml every night."
  • The official Xozal/Xyzal oral-solution concentration is 0.5 mg/ml in the European patient leaflet and SmPC.
  • The child is 5 years old on this date, not yet 6.
  • The dose has since been confirmed as prescribed: 10 ml every night.
  • The symptom picture includes eczema-related itch and urticaria/hives.

Dose interpretation

  • 10 cc means 10 ml.
  • If the instruction truly means 10 ml of a 0.5 mg/ml solution, that equals 5 mg levocetirizine each night.
  • In the same UK/European leaflet, 10 ml once daily is the listed dose for children aged 6 to 12 years, while children aged 2 to 6 years are listed at 2.5 ml twice daily (emc PIL, emc SmPC).
  • In the current US FDA label, children aged 6 months to 5 years are listed at 2.5 ml once daily in the evening (FDA label, DailyMed).
  • The FDA label also says that in children aged 6 months to 5 years, the 1.25 mg once-daily dose should not be exceeded because that exposure is already comparable to an adult 5 mg dose (FDA label).

What broader eczema guidance says

  • NICE says do not routinely use oral antihistamines for childhood eczema, but says a 1-month trial of a non-sedating antihistamine can be offered when eczema is severe or when there is severe itching or urticaria (NICE CG57).
  • NICE separately says that if sleep disturbance is having a significant impact during an acute flare, a short 7- to 14-day trial of an age-appropriate sedating antihistamine can be offered (NICE CG57).
  • The American Academy of Dermatology says antihistamines do not treat eczema itself and do not reliably stop eczema itch; a sedating antihistamine may sometimes be used briefly to help a child sleep, while the eczema itself still needs direct treatment (AAD antihistamines page).
  • AAAAI similarly states that oral antihistamines do not reduce eczema itch well because eczema itch is not mainly histamine-driven; sedating antihistamines may help sleep, but they are not core eczema treatment (AAAAI eczema overview).

Dose references worth keeping visible

Source Indication / context Age band Stated oral-solution dose
Xyzal/Xozal emc patient leaflet / SmPC Allergic rhinitis and urticaria <2 years Not supported / not recommended in the EU/UK product information
Xyzal/Xozal emc patient leaflet / SmPC Allergic rhinitis and urticaria 2 to 6 years 2.5 ml twice daily (1.25 mg twice daily; total 2.5 mg/day)
Xyzal/Xozal emc patient leaflet / SmPC Allergic rhinitis and urticaria 6 to 12 years 10 ml once daily (5 mg/day)
Xyzal/Xozal emc patient leaflet / SmPC Allergic rhinitis and urticaria 12+ years 10 ml once daily (5 mg/day)
FDA prescribing information Perennial allergic rhinitis 6 months to 2 years 2.5 ml once daily in the evening (1.25 mg/day); should not be exceeded
FDA prescribing information / DailyMed Chronic idiopathic urticaria 6 months to 5 years 2.5 ml once daily in the evening (1.25 mg/day); should not be exceeded
FDA prescribing information / DailyMed Chronic idiopathic urticaria 6 to 11 years 5 ml once daily in the evening (2.5 mg/day); should not be exceeded
FDA prescribing information / DailyMed Chronic idiopathic urticaria 12+ years 10 ml once daily in the evening (5 mg/day); some patients may be controlled with 5 ml once daily

Important interpretation

  • For this 5-year-old, 10 ml nightly remains higher than the standard product-label dosing references above.
  • With the additional information that the child also has urticaria/hives, the prescription is more plausibly being used as a clinician-directed antihistamine strategy for a mixed eczema-plus-urticaria presentation, not as standard eczema dosing alone.
  • In chronic urticaria, professional urticaria guidelines use second-generation H1-antihistamines as first-line therapy and may increase the dose up to fourfold when standard dosing fails (AAD urticaria guideline summary).
  • Even so, the product-label dosing for a 5-year-old is still lower, so this should be understood as a higher-than-label pediatric dose, not as ordinary labeled dosing.

Practical questions to document

  • Is the target problem eczema-related itch, allergic rhinitis, urticaria/hives, or a combined picture?
  • Is the medicine meant for daily continuous use, temporary use during a flare, or seasonal/allergy periods only?
  • What benefit should count as success: fewer wakings, less scratching, less hives, less sneezing/runny nose, or something else?
  • Which side effects should count as a stop-and-call signal: daytime drowsiness, agitation, mood change, urinary difficulty, or no clear benefit?

Suggested home tracking while this is being clarified

  • bedtime itch score
  • number of night wakings / scratching episodes
  • daytime sleepiness or irritability
  • hives, sneezing, runny nose, or watery eyes if those symptoms are part of the picture
  • any clear benefit within the first few days to 4 weeks
  • whether hives clearly improve at the confirmed 10 ml nightly dose
  • whether the child seems unusually sleepy the next morning

References

  • UCB Pharma Ltd. Xyzal 0.5 mg/ml oral solution - Patient Information Leaflet (PIL). Last updated 2022-07-14. Source type: official product leaflet. URL: https://www.medicines.org.uk/emc/files/pil.348.pdf
  • UCB Pharma Ltd. Xyzal 0.5 mg/ml oral solution - Summary of Product Characteristics (SmPC). Last updated 2022-07-15. Source type: official product monograph. URL: https://www.medicines.org.uk/emc/product/348/smpc
  • U.S. Food and Drug Administration. XYZAL (levocetirizine dihydrochloride) prescribing information. Revised 2025-07. Source type: official prescribing information. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022064s040,022157s022lbl.pdf
  • DailyMed / NIH. CHILDRENS XYZAL ALLERGY - levocetirizine dihydrochloride solution. Accessed 2026-04-09. Source type: official drug label mirror. URL: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a33f2704-d350-428b-b467-91f4775ce17f
  • NICE. Atopic eczema in under 12s: diagnosis and management (CG57). Updated 2023. Source type: official guideline. URL: https://www.nice.org.uk/guidance/cg57/chapter/Recommendations
  • American Academy of Dermatology. Eczema treatment: Antihistamines. Accessed 2026-04-09. Source type: professional society educational page. URL: https://www.aad.org/public/diseases/eczema/childhood/treating/antihistamines
  • American Academy of Allergy, Asthma & Immunology. Eczema (Atopic Dermatitis) | Symptoms, Treatment & Management. Accessed 2026-04-09. Source type: professional society educational page. URL: https://www.aaaai.org/tools-for-the-public/conditions-library/allergies/eczema-%28atopic-dermatitis%29-overview
  • American Academy of Dermatology. Key messages: Urticaria guidelines. Accessed 2026-04-09. Source type: professional society guideline summary. URL: https://www.aad.org/member/clinical-quality/guidelines/urticaria